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Increased resistance is due to:
 y liver architectural disturbance, with di-
stortion of vascular architecture by fibro-
sis, scarring, regenerative nodules, throm-
bosis (mechanical or fixed component, 
not modifiable by pharmacological tre-
atment); and
 y functional hepatic microcirculation alte-
rations (active contraction of portal/sep-
tal myofibroblasts, activated stellate cells, 
portal venules – the so-called dynamic 
component, modifiable by drugs). This ac-
tive intrahepatic vascular contraction is a 
consequence of an unbalance between va-
soconstrictor substances (endothelin, an-
giotensin II, vasopressin, tromboxane A2, 
leukotrienes, etc.) and vasodilators (nitric 
oxide [NO], CO, prostacycline, etc.) [6].
Portal blood flow in its turn increases 
because of enhanced production of vasodi-
INTRODUCTION
Portal hypertension (PH) is a severe com-
plication of liver cirrhosis [1]. Patients with 
PH run the risk of developing gastro-eso-
phageal varices and massive gastrointestinal 
bleeding, ascites, hepatorenal syndrome, and 
hepatic encephalopathy [2].
The portal pressure gradient is the diffe-
rence between portal pressure and the pres-
sure at the hepatic veins/inferior vena cava 
level; it represents the hepatic perfusion 
pressure [3]. In patients with cirrhosis, por-
tal pressure increases because of increased 
intrahepatic vascular resistance and incre-
ased portal blood flow [4]. The interaction 
between portal blood flow and the vascular 
resistance that opposes that flow is defined 
by the Ohm’s law (∆P = Q × R), where ∆P is 
the portal pressure gradient, Q is portal blo-
od flow and R is the vascular resistance [5].
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Portal hypertension (PH) is a severe complication of liver cirrhosis. Patients with PH run the 
risk of developing gastro-esophageal varices and massive gastrointestinal bleeding, ascites, 
hepatorenal syndrome, and hepatic encephalopathy.
Portal blood flow in its turn increases because of enhanced production of vasodilators, increased 
eNOS activity and NO release, systemic and splanchnic vasodilation, hyperkinetic circulation, 
and hyposensitivity to vasoconstrictors. Thus, it is now widely recognized that this hyperkinetic 
(hyperdynamic) circulation that characterizes liver cirrhosis is the main cause of the complications 
of the disease.
This review is aimed at addressing the role of vasoconstrictor treatment in patients suffering 
from complications of decompensated cirrhosis, offering practical suggestions for the management 
of this treatment at bedside.
In particular, the management of terlipressin in patients with cirrhosis, its side effects and the 
efficacy of this vasoconstrictor will be examined.
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lators, increased eNOS activity and NO re-
lease, systemic and splanchnic vasodilation, 
hyperkinetic circulation, and hyposensiti-
vity to vasoconstrictors [7]. Thus, it is now 
widely recognized that this hyperkinetic 
(hyperdynamic) circulation that characte-
rizes liver cirrhosis is the main cause of the 
complications of the disease [8].
This review is aimed to address the role of 
vasoconstrictor treatment in patients suffe-
ring from complications of decompensa-
ted cirrhosis, offering practical suggestions 
for the management of this treatment at 
bedside.
PATHOPHYSIOLOGY OF PH AND 
HYPERKINETIC CIRCULATION
Increased intra-hepatic resistance to portal 
blood flow is the primary factor leading to 
portal hypertension in cirrhosis [1]. As un-
derlined above, the increased intra-hepatic 
resistance is the consequence of both the 
architectural disturbances caused by the 
cirrhotic process and of an active contrac-
tion of several cellular elements [8]. This 
latter represents the dynamic and modifia-
ble component of intra-hepatic resistance, 
accounting for up to 30-40% of the intra-
hepatic vascular resistance in cirrhosis [9]. 
Contractile elements influencing the hepatic 
vascular bed include vascular smooth muscle 
cells of the intra-hepatic vasculature, activa-
ted hepatic stellate cells (HSCs) and hepatic 
myofibroblasts, that may compress the rege-
nerating nodules or venous shunts within 
the fibrous septa [8]. Vasoactive mediators, 
either vasoconstrictors or vasodilators, may 
modulate intrahepatic vascular resistan-
What is already known about this issue?
 y Portal hypertension (PH) is a severe complication of liver cirrhosis. 
It is secondary to increased intra-hepatic resistance to portal blood 
flow and to massive splanchnic arteriolar vasodilation, due to an 
excess of NO within the splanchnic circulation
 y The hyperkinetic (hyperdynamic) circulation that characterizes liver 
cirrhosis is the main cause of the complications of the disease, such 
as hepatorenal syndrome (HRS)
 y HRS is a common complication of patients with cirrhosis, due to 
functional renal impairment without an identifiable cause
 y The arterial vasodilation in the splanchnic circulation plays a cen-
tral role in the renal function deterioration, with activation of 
renin-angiotensin and sympathetic nervous systems, leading to an 
uncontrolled renal vasoconstriction
ce either in health or during liver disease, 
whatever the location where they act [8,9].
In normal liver, the hepatic endothelium 
produces vasodilatory substances in response 
to increased blood volume, blood pressure, 
or vasoconstrictor agents, in an attempt 
to counteract the concomitant increase in 
intravascular pressure [10]. However, the 
cirrhotic liver cannot attenuate the increased 
portal blood flow caused by PH [3]. This so-
called “endothelial dysfunction” in cirrhosis 
has been attributed to reduced nitric oxide 
(NO) bioavailability and to increased vaso-
constrictor substances [8]. Such imbalance 
between endogenous vasoconstrictor and 
vasodilator factors observed in the cirrho-
tic liver is thought to be implicated in the 
pathogenesis of the dynamic component of 
the increased intra-hepatic resistance of the 
cirrhotic liver [10].
In other words, during the course of 
cirrhosis an excess of vasoconstrictors with 
respect to vasodilators does progressively 
occur. The main vasoconstrictors are COX1-
derived prostanoids, thromboxane, endo-
thelin, angiotensin, vasopressin, and nore-
pinephrine [3,8,10].
In addition, reduced NO bioavailability 
within the cirrhotic liver leads to failure to 
counteract the increased intrahepatic vaso-
constriction [11]. Endothelial NO synthase 
(eNOS) is responsible for most of the va-
scular NO produced into the normal liver 
[12]. By contrast, in the cirrhotic liver, there 
is a reduced NO bioavailability that plays a 
major role in increasing intra-hepatic vascu-
lar resistance and thereby worsening portal 
hypertension [13]. Decreased NO produc-
tion occurs despite a normal expression of 
eNOS mRNA and normal levels of eNOS 
protein [8,10], and has been attributed, at le-
ast in part, to reduced eNOS activity caused 
by several posttranslational alterations in the 
regulation of the enzyme such as increased 
caveolin expression, or a defect of the essen-
tial cofactor of eNOS (tetrahydrobiopterin), 
decreased eNOS phosphorylation, and in-
creased levels of asymmetric dimethylargi-
nine among others [10].
Finally, in patients with decompensated 
cirrhosis there is a massive splanchnic arte-
riolar vasodilation, due to an excess of NO 
within the splanchnic circulation. This vaso-
dilation is thought to be secondary to PH 
and shear stress, that determines hyperacti-
vation of eNOS gene within the extra-he-
patic splanchnic smooth cells, with increased 
eNOS activity and excess NO production. 
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This reduced NO availability within the 
intrahepatic circulation and the NO excess 
within the splanchnic extrahepatic circu-
lation has been defined as “the paradox of 
NO in liver cirrhosis”: too much (outside 
the liver), not enough (within the liver) [14].
PH MEASUREMENTS
The definition of portal hypertension is 
based on a pressure measurement [15]. Por-
tal pressure measurement is usually deter-
mined indirectly , by subtracting the free 
hepatic venous pressure (FHVP) from the 
wedged hepatic venous pressure (WHVP). 
In liver cirrhosis, WHVP equals portal 
(sinusoidal) pressure, and FHVP equals 
inferior vena cava pressure [16]. This gra-
dient, the so-called hepatic venous pressure 
gradient (HVPG), accurately reflects the 
degree of PH in the majority of liver dise-
ases [16,17]. The technique of hepatic vein 
catheterization with measurement of the 
HVPG is safe and reproducible [3]. Seve-
ral studies have shown a good correlation 
between direct portohepatic measurements 
and HVPG measurements (using a balloon 
catheter) both in alcoholic and viral cirrho-
sis [3]. Thus, the HVPG measurement 
using a balloon catheter is now considered 
the gold standard for portal pressure eva-
luation [16].
PH is defined by a pathological increase of 
the HVPG values above the normal upper 
limit of 5 mmHg, while clinically significant 
PH (CSPH) is defined by an increase in 
HVPG values to a threshold above appro-
ximately 10-12 mmHg [2,16,17]. Varices 
do not bleed when the HVPG is below 12 
mmHg [1].
HVPG determination is a safe and reliable 
tool to measure the degree of portal hyper-
tension, with a very low rate of complica-
tions. However, it is an invasive technique, 
not inexpensive, which requires well-expe-
rienced hepatologists, specific equipments 
and expensive disposable materials [18].
Thus, due to these methodological and 
technical difficulties, the measurement of 
PH is not immediate and is performed only 
in a limited number of specialized centres 
[19].
In clinical practice, HVPG measurement 
could have several applications [20-23], 
such as:
 y Evaluation of the risk of variceal hae-
morrhage.
 y Assessment of haemodynamic response 
to pharmacological therapy.
 y Definition of prognosis (cirrhosis and 
acute variceal bleeding).
 y Pre-operative evaluation of cirrhotic pa-
tients candidates to hepatic resection.
Furthermore, HVPG measurement could 
have a prognostic value. It has been shown 
that the HVPG at different cut-off levels is 
a predictor of long-term survival in cirrhotic 
patients without previous variceal bleeding 
at inclusion in the study [24]. Several studies 
have found a significant higher survival in 
patients in whom HVPG levels were below 
the cut-off than in those with HVPG above 
the cut-off [25]. The predictive HVPG value 
was identified between 12 and 20.8 mmHg. 
Further, it has been found that early mea-
surement of HVPG in patients with acute 
variceal bleeding could have a negative pro-
gnostic value if ≥ 20 mmHg [26,27].
PHARMACOLOGICAL PROFILE OF 
VASOCONSTRICTORS
In clinical practice, at least four vasocon-
strictors are used: somatostatin, octreotide, 
terlipressin and midodrine.
Somatostatin (SMS) is a 14-aminoacid 
peptide, with well-known vasoconstricti-
ve properties. SMS provokes splanchnic 
vasoconstriction with a decrease in portal 
blood flow, acting through inhibition of 
endogenous vasodilators (glucagon, VIP, P 
substance), although it exerts also a direct 
vasoconstrictive effect, mediated by activa-
tion of receptor subtype 2. Although SMS 
treatment is generally safe and well tolerated, 
in some patients several side effects are seen. 
The main reported side effects of SMS are: 
hyper/hypoglycaemia, diarrhoea, hyperten-
sion, chest pain, flushing [28].
Octreotide (OCT) is a synthetic 8-pep-
tide, sharing with SMS the 4 aminoacids 
responsible for biological effects. Reported 
side effects of OCT are: dizziness, fati-
gue, headache, diarrhoea, abdominal pain, 
flushing, nausea [8].
On the whole, SMS and OCT have a 
lower incidence of complications, major 
adverse events (AEs) and mortality than 
vasopressin and terlipressin.
Terlipressin (triglycyl-lysine-vasopres-
sin) is a synthetic analogue of the natural 
hormone arginin-vasopressin. Terlipressin 
is the most used drug in the treatment of 
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hepatorenal syndrome (HRS). Terlipres-
sin is a prohormone of lysine-vasopressin 
(triglycyl-lysine-vasopressin). Following 
intravenous administration, the glycyl resi-
dues are cleaved from the prohormone by 
endothelial peptidases, allowing prolonged 
release of lysine-vasopressin. This mecha-
nism prolongs the half-life of terlipressin, 
enabling administration in divided doses 
without the need for an infusion as with 
vasopressin and minimizes systemic toxi-
city [29].
Terlipressin has affinity for both V1 and 
V2 receptors. Terlipressin selectively causes 
splanchnic and extrarenal vasoconstric-
tion by stimulation of V1 receptors, which 
are predominantly located in the smooth 
muscles of the arterial vasculature in the 
splanchnic region, and thereby reduces 
splanchnic blood flow and portal pressure 
[30]. Following terlipressin administration 
for 30 minutes there is an increase in mean 
arterial pressure and systemic vascular resi-
stance while the heart rate, cardiac output, 
hepatic venous pressure gradient, and portal 
venous blood flow decrease [31].
Reduction in portal pressure results in 
amelioration in the hyperdynamic circula-
tion, thereby improving the effective circu-
latory volume, and renal perfusion pressure 
[32].
V2 receptor stimulation by terlipressin 
increases water reabsorption in the renal 
collecting ducts by increasing the number 
of aquaporin-2 water channels in the apical 
plasma membrane [14,16]. Hyponatraemia 
may occur in some patients [33].
Due to prolonged vasoconstrictor action 
terlipressin can be given by intermittent i.v. 
injections (preferably in bleeding) or by con-
tinuous infusion (HRS).
Although terlipressin is slowly cleaved 
in vivo to vasopressin, it is also believed to 
have an intrinsic vasoconstrictor effect on its 
own. Terlipressin has a much greater effect 
on vascular vasopressin receptors (V1) than 
on renal vasopressin receptors (V2) [34].
Midodrine  is an alpha1-adrenergic ago-
nist [29]. Data supporting the use of mido-
drine were mostly observational in nature 
and have not been compared directly to 
treatment with terlipressin or noradrenali-
ne. Oral administration of this alpha-adre-
nergic agonist improved systemic and renal 
haemodynamics in nonazotaemic cirrhotic 
patients but had no effect in patients with 
HRS [30]. However, when midodrine was 
combined with plasma volume expansion 
and octreotide, a nonspecific inhibitor of the 
release of endogenous vasodilators, there was 
significant improvement in both the syste-
mic and renal haemodynamics and urinary 
sodium excretion, although renal function 
did not return to normal despite suppression 
of all measured neurohormonal systems to 
within the normal range [33].
THE ROLE OF VASOCONSTRICTORS 
IN THE TREATMENT OF 
COMPLICATION OF CIRRHOSIS
Gastroesophageal varices
Gastroesophageal varices are present 
in almost half of patients with cirrhosis 
at the time of diagnosis, with the highest 
rate among patients with Child-Turcotte-
Pugh class B or C [35]. Development and 
growth of gastroesophageal varices each 
occur at a rate of 7% per year [1]. The 
1-year rate of a first variceal haemorrhage 
is approximately 12% (5% for small varices 
and 15% for large varices) [35]. Besides va-
riceal size, red wale marks on varices and 
advanced liver disease (Child class B or C) 
identify patients at a high risk for variceal 
haemorrhage [1].
The 1-year rate of recurrent variceal hae-
morrhage is approximately 60% [35]. The 
6-week mortality with each episode of 
variceal haemorrhage is approximately 15 
to 20%, ranging from 0% among patients 
with Child class A disease to approxima-
tely 30% among patients with Child class 
C disease [1,2].
Available therapies for varices and variceal 
haemorrhage can be classified according to 
whether they act on the physiologic mecha-
nisms of portal hypertension [36].
Acute variceal bleeding is the most seve-
re consequence of portal hypertension. The 
treatment of this entity should involve the 
initial control of haemorrhage and preven-
tion of early rebleeding [37]. Endoscopic 
sclerotherapy or band ligation have been 
shown to be highly effective in the control 
of both these processes [38]. Both proce-
dures stop bleeding in about 80% to 90% of 
patients [1]. On the other hand, vasoactive 
drugs, such as somatostatin and terlipressin, 
are as effective as endoscopic sclerotherapy 
for the arrest of the acute episode of blee-
ding and prevention of early rebleeding [39]. 
However, haemodynamic and clinical data 
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are not so consistent when other agents such 
as octreotide are employed [40].
Patients who have Child class A or B di-
sease or who have an HVPG of less than 20 
mmHg have a low or intermediate risk and 
should receive standard therapy – specifical-
ly, the combination of a safe vasoconstrictor 
(terlipressin, somatostatin, or analogues such 
as octreotide or vapreotide, administered 
from the time of admission and maintai-
ned for 2 to 5 days) and endoscopic therapy 
(preferably endoscopic variceal ligation, per-
formed at diagnostic endoscopy < 12 hours 
after admission), together with short-term 
prophylactic antibiotics (either norfloxacin 
or ceftriaxone) [41].
A recent metanalysis showed that the ef-
ficacy of endoscopic therapy in achieving 
initial control of bleeding and 5-day hae-
mostasis is significantly improved when so-
matostatin or its derivatives are added to the 
endoscopic treatment regimen [42].
Hepatorenal syndrome (HRS)
HRS is a common complication of pa-
tients with cirrhosis, due to functional renal 
impairment without an identifiable cause 
[43,44]. Approximately 39% of patients 
with cirrhosis and ascites will develop HRS 
during the course of the disease. Criteria for 
the diagnosis of HRS developed by the In-
ternational Club of Ascites [45] include the 
following: presence of cirrhosis and ascites, 
serum creatinine higher than 1.5 mg/dl, no 
improvement in serum creatinine (decrea-
se equal to or less than 1.5 mg/dl) after at 
least 48 hours of diuretic withdrawal and 
volume expansion with albumin, absence of 
shock, no current or recent treatment with 
nephrotoxic drugs, absence of parenchymal 
kidney disease as indicated by proteinuria 
(500 mg/day), microhaematuria (50 red blo-
od cells/high power field), and/or abnormal 
renal ultrasound scanning. Type 1 HRS was 
defined as a rapidly progressive reduction 
in renal function, e.g., a doubling of serum 
creatinine to greater than 2.5 mg/dl in less 
than 2 weeks and failure of renal function 
to improve following diuretic withdrawal 
and plasma volume expansion. Type 2 HRS 
was defined as serum creatinine greater than 
1.5 mg/dl, which follows a steady or slowly 
progressive course [46].
Again, HRS pathogenesis involves the 
interplay between the activation of vaso-
constrictor systems and the reduction in 
the activity of vasodilator systems [44]. 
The arterial vasodilation in the splanchnic 
circulation plays a central role in the renal 
function deterioration and the haemodyna-
mic changes and is mediated by an increa-
sed production and/or activity of local va-
sodilators, with nitric oxide being the most 
important. As the liver disease progresses 
in severity, a critical level of hypoperfusion 
is achieved, with subsequent activation of 
renin-angiotensin and sympathetic nervous 
systems [47].
Renal vasodilatory systems are not able 
to offset the maximal effect of endogenous 
vasoconstrictors, leading to an uncontrol-
led renal vasoconstriction [2,4,5]. This 
peripheral arterial vasodilation theory for 
HRS has resulted in several pharmacolo-
gic treatment of HRS with systemic va-
soconstrictors [10,11]. Preliminary studies 
have been reported using α-adrenergic 
agonists (midodrine and noradrenaline), 
vasopressin analogues (ornipressin and 
terlipressin), and somatostatin analogue 
(octreotide) [12,13]. Octreotide in com-
bination with midodrine and albumin in-
fusion improved renal and systemic hae-
modynamics by the systemic vasoconstric-
tor effect of midodrine and the inhibition 
of endogenous vasodilator release action 
of octreotide [14].
The choice of drug and the schedule of 
treatment varied across these studies. To 
date, terlipressin is the most widely used 
vasoconstrictor in the treatment of type-1 
HRS [48,49].
Partial or complete reversal of type-1 HRS 
was observed in almost 59% of patients 
[50,51]. Nevertheless, the preliminary re-
sults of the two first controlled clinical trials 
comparing terlipressin and albumin with 
albumin alone did not confirm a beneficial 
effect of terlipressin and albumin on 2- or 
3-month survival in patients with type-1 
HRS [50,51].
More recently, Caraceni et al. suggested 
long-term treatment with terlipressin plus 
albumin (62 days to eight months) as a 
bridge to liver transplantation in cirrhotic 
patients with recurrent HRS [52].
In clinical practice, Italian regulatory 
Agency suggests the use of terlipressin in 
cirrhotic patients with HRS type I, provided 
that they fulfil the criteria for the diagno-
sis of HRS as defined by the International 
Ascites Club [45]; terlipressin should be 
administered at a dosage of 2-3 mg/die by 
continuous infusion or by intermittent i.v. 
boli of 0.5 mg every 4-6 hours.
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Results with other vasoconstrictors (octre-
otide, midodrine, adrenaline) are still preli-
minary and conflicting [53-55].
Refractory ascites
Ascites is a common complication of 
liver cirrhosis, occurring in more than 50-
60% of the patients within 10 years of the 
diagnosis. It develops late during the course 
of the disease, when there are severe portal 
hypertension and hepatic insufficiency; its 
appearance represents a critical landmark 
in the natural history of the disease, with a 
significant worsening of the prognosis [56].
Furosemide and spironolactone – toge-
ther with salt restriction – are the diure-
tics more commonly used in the treatment 
of mild to moderate cirrhotic ascites [57]. 
Furosemide inhibits chloride and sodium 
reabsorption in the thick ascending limb of 
the loop of Henle, but has no effect on the 
distal nephron. Spironolactone undergoes 
extensive metabolism leading to numerous 
biologically active compounds, the most im-
portant quantitatively being canrenone. In 
the kidney, these compounds act by compe-
titively inhibiting the tubular effect of aldo-
sterone in the distal nephron [58].
In 5-10% of patients, ascites cannot be 
mobilized, or its early recurrence (e.g. after 
therapeutic paracentesis) cannot be pre-
vented by medical treatment. This condi-
tion is known as “refractory ascites” [59]. 
This condition might be secondary to the 
lack of response to sodium restriction and 
maximal diuretic treatment (160 mg/day of 
furosemide and 400 mg/day of spironolac-
tone – diuretic-resistant ascites) or to the 
development of diuretic-induced compli-
cations that might preclude the use of an 
effective diuretic dosage (diuretic-intractable 
ascites) [60].
Which are the new findings?
 y Type-1 HRS is a life-threatening complications of cirrhosis, with 
high mortality rates in the short term period
 y The use of vasoconstrictors in combination with plasma expanders 
(terlipressin plus albumin) seems to be able to reverse rapidly pro-
gressive renal failure
 y Partial or complete reversal of type-1 HRS was observed in up to 
60% of patients receiving treatment with terlipressin plus albumin, 
and more recent data suggest that terlipressin seems to be able to 
reduce mortality in these subjects
 y Results with other vasoconstrictors are still preliminary and con-
flicting
The first-line treatment of refractory asci-
tes consists in repeated total paracenteses 
[56]. In the case of exceedingly high fre-
quency of paracentesis, the use of transju-
gular intrahepatic portosystemic shunts 
(TIPS) should be taken into consideration 
[61]. Patients may continue to receive diu-
retic treatment, if tolerated.
Terlipressin has been proposed for the tre-
atment of refractory ascites, in association 
with the prolonged infusion of human albu-
min, but to date its use in cirrhotic patients 
with refractory ascites and normal renal 
function should be considered still preli-
minary [62]. A recent study [63] showed a 
synergistic effect of terlipressin when added 
to albumin and diuretics in patients with re-
fractory ascites and normal renal function, 
suggesting that albumin might enhance the 
vasoconstrictive response to terlipressin. This 
might contribute to counterbalance the ne-
gative effects of systemic vasodilation, which 
characterize the hyperdynamic circulation of 
cirrhotic patients [63].
MANAGEMENT OF SIDE EFFECTS 
OF VASOCONSTRICTORS
In everyday clinical practice the most 
used vasoconstrictors in cirrhotic patients 
are somatostatin and terlipressin. The use of 
SMS is limited to the control of acute vari-
ceal bleeding, whilst terlipressin treatment 
is employed for the management of several 
complications of cirrhosis: acute variceal 
bleeding, HRS type I, refractory ascites with 
normal renal function.
However, while adverse events during tre-
atment with SMS are rather rare and usually 
not severe (hyper/hypoglycaemia, diarrhoea, 
hypertension, chest pain, flushing), side effects 
of terlipressin are much more frequent, more 
severe, more difficult to manage, and – al-
though rarely – even life threatening [29-33].
A randomized prospective double-blind, 
placebo-controlled trial of terlipressin for 
type I HRS [50] showed an higher incidence 
of severe adverse events up to 30 days post-
treatment in patients treated with terlipres-
sin (8.9% vs. 1.8%), with a rate of withdrawal 
due to adverse events (AEs) up to 7 days of 
5.4% vs. 0%. In another patients’ series, the-
re were 4% of myocardial infarction, 13% of 
intestinal ischaemia, 9% of arrhythmias, and 
30% of circulatory overload [51].
Due to its ADH-like action (arginin-
vasopressin effects), terlipressin might in-
The main adverse events during terlipressin therapy
 y Myocardial ischaemia or infarction, cardiac arrhythmias
 y Arterial hypertension
 y Severe hyponatraemia, seizures, loss of consciousness
 y Pulmonary hypertension, dyspnoea
 y Headache
 y Abdominal pain, intestinal ischaemia or infarction
 y Peripheral ischaemia
 y Acute vasculitis-like lesions
 y Raynaud’s phenomenon
 y Peripheral tissue necrosis
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duce severe hyponatraemia, that might be 
misinterpreted as hepatic encephalopathy. 
Solà et al. [64] found that the development 
of hyponatraemia was common in cirrhotic 
patients treated with terlipressin because of 
GI bleeding. During the 5-days treatment 
period, 67% of the patients developed acute 
reduction in serum sodium concentrations, 
which was marked (reduction > 10 mEq/l) in 
up to 36% of them, and associated with neu-
rological manifestations in some patients. 
Similar findings were reported by Krag and 
coworkers [65].
As to cardiovascular adverse events, terli-
pressin treatment might induce myocardial 
infarction [66], severe bi-ventricular dysfun-
ction [67], and Tako-Tsubo syndrome (also 
known as transient left ventricular apical 
ballooning syndrome), a clinical entity cha-
racterized by reversible left ventricular apical 
wall motion abnormalities, typical electro-
cardiographic features, and minor increase 
of serum heart enzymes [68].
Other relevant side effects, sometimes se-
vere, are peripheral ischemia [69], cutaneous 
necrosis [70,71], haemorragic blistering of 
the skin [72], and even severe extensive epi-
dermal necrosis [73].
In Table I some advice are listed in order 
to avoid and diagnose the adverse events 
caused by terlipressin.
Predictors of adverse events during terlipressin
 y Elderly
 y Male gender
 y Coronary heart disease
 y Arterial hypertension
 y History of arrhytmias
 y Illicit drug abuse (cocaine)
 y Heavy smokers
 y Obesity
 y Chronic obstructive pulmonary disease (COPD)
 y Previous Raynaud’s phenomenon
 y Spontaneous bacterial peritonitis (SBP)
 y Peripheral venous insufficiency
Timing as to treatment Advice to manage terlipressin adverse events
Before 1. Carefully consider risk factors for adverse events
2. Use terlipressin cautiously in patients with known coronary heart 
disease or history of arrhytmias
3. Evaluate baseline serum sodium concentrations
4. Avoid terlipressin treatment in patients with EKG abnormalities or 
echocardiographic changes (e.g., dyskinesia)
5. When major AEs might be expected, in patients with esophageal bleeding 
choose somatostatin first-line treatment, or consider endoscopic 
treatment
During 1. Do not prolong treatment beyond 14 days
2. Strictly monitor serum sodium concentrations
3. Carefully evaluate mental status of the patient 
4. Early identify neurological symptoms or signs (hepatic encephalopathy?)
5. Strictly monitor heart rate/rhythm, blood pressure, electrocardiogram 
(EKG)
6. Consider combination treatment with transdermal nitrates
7. Immediately withdraw treatment in the case of major AEs
8. In bleeding patients, consider shift to SMS
After 1. Continue follow-up
2. Remember that AEs might appear up to 30 days after treatment
3. Weekly evaluate the patients
4. Monitor heart rate, blood pressure, EKG
5. In the case of abnormal mental status or dizziness, evaluate serum 
Na+ concentrations (diagnosis of hyponatraemia versus hepatic 
encephalopathy)
Table I. How to manage 
terlipressin adverse 
events
The first-line treatment of refractory asci-
tes consists in repeated total paracenteses 
[56]. In the case of exceedingly high fre-
quency of paracentesis, the use of transju-
gular intrahepatic portosystemic shunts 
(TIPS) should be taken into consideration 
[61]. Patients may continue to receive diu-
retic treatment, if tolerated.
Terlipressin has been proposed for the tre-
atment of refractory ascites, in association 
with the prolonged infusion of human albu-
min, but to date its use in cirrhotic patients 
with refractory ascites and normal renal 
function should be considered still preli-
minary [62]. A recent study [63] showed a 
synergistic effect of terlipressin when added 
to albumin and diuretics in patients with re-
fractory ascites and normal renal function, 
suggesting that albumin might enhance the 
vasoconstrictive response to terlipressin. This 
might contribute to counterbalance the ne-
gative effects of systemic vasodilation, which 
characterize the hyperdynamic circulation of 
cirrhotic patients [63].
MANAGEMENT OF SIDE EFFECTS 
OF VASOCONSTRICTORS
In everyday clinical practice the most 
used vasoconstrictors in cirrhotic patients 
are somatostatin and terlipressin. The use of 
SMS is limited to the control of acute vari-
ceal bleeding, whilst terlipressin treatment 
is employed for the management of several 
complications of cirrhosis: acute variceal 
bleeding, HRS type I, refractory ascites with 
normal renal function.
However, while adverse events during tre-
atment with SMS are rather rare and usually 
not severe (hyper/hypoglycaemia, diarrhoea, 
hypertension, chest pain, flushing), side effects 
of terlipressin are much more frequent, more 
severe, more difficult to manage, and – al-
though rarely – even life threatening [29-33].
A randomized prospective double-blind, 
placebo-controlled trial of terlipressin for 
type I HRS [50] showed an higher incidence 
of severe adverse events up to 30 days post-
treatment in patients treated with terlipres-
sin (8.9% vs. 1.8%), with a rate of withdrawal 
due to adverse events (AEs) up to 7 days of 
5.4% vs. 0%. In another patients’ series, the-
re were 4% of myocardial infarction, 13% of 
intestinal ischaemia, 9% of arrhythmias, and 
30% of circulatory overload [51].
Due to its ADH-like action (arginin-
vasopressin effects), terlipressin might in-
The main adverse events during terlipressin therapy
 y Myocardial ischaemia or infarction, cardiac arrhythmias
 y Arterial hypertension
 y Severe hyponatraemia, seizures, loss of consciousness
 y Pulmonary hypertension, dyspnoea
 y Headache
 y Abdominal pain, intestinal ischaemia or infarction
 y Peripheral ischaemia
 y Acute vasculitis-like lesions
 y Raynaud’s phenomenon
 y Peripheral tissue necrosis
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CONCLUSIONS
Despite these adverse events, it should be 
underlined that terlipressin decreases failu-
re of initial haemostasis by 34%, decreases 
mortality by 34%, and is considered a first-
line treatment for esophageal bleeding [74]. 
Terlipressin in combination with albumin 
reverses type 1 HRS in 33-60% of cases and 
is the only treatment with proven efficacy in 
randomized trials [75].
Thus, we can conclude that the safety pro-
file is favourable when considering the cli-
nical efficacy and the high mortality caused 
by the complications of cirrhosis. Mortality 
and withdrawal of terlipressin due to adverse 
events occurs in less than 1% of cases. Mild 
adverse events related to terlipressin tre-
atment occur in 10-20% of patients.
Among available vasoactive drugs, terli-
pressin is probably the most effective phar-
macological therapy for bleeding and the 
only accepted treatment for HRS, but SMS 
appears to be also effective with less side ef-
fects in variceal bleeding [1].
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Which are the implications in clinical practice?
 y Side effects of terlipressin are more severe and more difficult to manage than those of other 
vasoconstrictors, and – although rarely – even life threatening
 y Hyponatraemia and acute ischaemia (heart, gut, skin, etc.) have been frequently reported
 y Anyway, the safety profile is favourable when considering the clinical efficacy and the high 
mortality caused by the complications of cirrhosis
 y Among available vasoactive drugs, terlipressin is probably the most effective pharmaco-
logical therapy for bleeding and the only accepted treatment for HRS, but SMS appears 
to be also effective with less side effects in variceal bleeding
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